Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7834.018 | 0.9708 | 0.9689 | 1.8951 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7834.018 | 1.0557 | 1.0580 | 1.8951 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7834.018 | 0.9321 | 0.9272 | 1.8951 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7834.018 | 0.9563 | 0.9534 | 1.8951 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7834.018 | 0.9232 | 0.9174 | 1.8951 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7834.018 | 0.9500 | 0.9466 | 1.8951 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7834.018 | 0.9019 | 0.8939 | 1.8951 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7835.018 | 0.9522 | 0.8242 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7835.018 | 1.0387 | 1.1479 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7835.018 | 1.0322 | 1.1227 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7835.018 | 1.0579 | 1.2230 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7835.018 | 0.9121 | 0.6826 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7835.018 | 0.7767 | 0.2444 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7835.018 | 0.8383 | 0.4363 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7835.018 | 0.8332 | 0.4198 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7835.018 | 0.7296 | 0.1067 | 0.5326 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7836.018 | 0.8792 | 0.7756 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7836.018 | 0.8890 | 0.7939 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7836.018 | 0.7466 | 0.5266 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7836.018 | 0.9783 | 0.9598 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7836.018 | 1.0456 | 1.0842 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7836.018 | 0.8695 | 0.7576 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7836.018 | 0.8936 | 0.8024 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7836.018 | 0.7832 | 0.5957 | 1.0819 | |
| HCC1954 | HER2amp | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7836.018 | 0.7161 | 0.4689 | 1.0819 |